IUGNF - Imugene (IUGNF) - Progress Continues With New Trial and ASCO Abstracts

Product Development Platforms Reach Clinical Trial Milestones. A Phase 1 dose escalation trial has begun treating patients with CF-hNIS Vaccinia, a product from Imugene's oncolytic virus platform. The trial will enroll patients with metastatic or advanced solid tumors. The company has also published abstracts from three trials at the ASCO annual meeting, held June 3-7. Vaccinia Platform Continues To Make Progress. Imugene is developing two vaccines from its oncologic virus platform, CF-hNIS Vaccinia and CHECKVacc, that deliver a genetically modified poxvirus to infect cancer cells. The virus takes over the cell functions, reproducing inside the cell. This causes the cell to die and burst, releasing new viral particles that infect other cancer cells and stimulating an immune response against the cancer cell antigens. CHECKVacc is currently in its second Phase 1 dosing cohort in triple negative breast cancer (TNBC). Read More >>